IGF-1 LR3 1mg

IGF-1 LR3 1mg — Research Overview

IGF-1 LR3 (Long R3 IGF-1) is a recombinant analogue of insulin-like growth factor 1 (IGF-1) that’s been tweaked with two specific structural changes: an N-terminal arginine extension (the R3) and a glutamic acid to arginine substitution at position 3 (the Long). These modifications aren’t just for show; they slash IGF-1 LR3’s affinity for IGF-binding proteins (IGFBPs) by about 1,000-fold compared to native IGF-1. Because IGFBPs usually lock up roughly 99% of circulating IGF-1 in an inactive state, cutting down that binding means there’s a much larger pool of free, biologically active peptide ready to hit the IGF-1 receptor (IGF-1R). This makes it a far more potent and longer-acting analogue than the natural version. It’s why researchers frequently use it to study IGF-1 receptor signalling and various anabolic pathways. This product is for research purposes only and is not intended for human administration; it should only be handled by qualified investigators.

Mechanism of Action

Much like endogenous IGF-1, IGF-1 LR3 kicks off the IGF-1R tyrosine kinase receptor. This triggers autophosphorylation and activates the PI3K/Akt/mTOR pathway—the main anabolic signalling cascade that manages protein synthesis, cell growth, and survival. It also switches on the MAPK/ERK pathway to drive cell proliferation and differentiation. Because IGF-1 LR3 isn’t really hindered by IGFBP sequestration, it maintains receptor occupancy at higher levels for much longer than native IGF-1. This leads to a more pronounced and sustained anabolic signal in both tissue culture and in vivo models.

Researchers often look at the relationship between IGF-1 LR3 and MGF 2mg to better understand muscle biology. While MGF is a splice variant of the IGF-1 gene that pops up locally when there’s mechanical stress, it mostly works on muscle satellite cells through a path that’s partially independent of IGF-1R. On the other hand, IGF-1 LR3 works systemically via IGF-1R to drive hypertrophic signalling in muscle cells that have already differentiated. Figuring out how these two parts of the IGF-1 system work together remains a major focus in current studies. This product is for research purposes only and is not intended for human administration; it should only be handled by qualified investigators.

Research Context

IGF-1 LR3 is a staple in cell biology, tissue engineering, and in vivo pharmacology research. Scientists often use it in cell culture to drive the proliferation of primary cells—especially myocytes, chondrocytes, and bone marrow-derived cells. Because it doesn’t bind as readily to IGFBPs, it works at much lower concentrations than native IGF-1. This makes it a practical, cost-effective choice for large-scale culture experiments.

When researchers look at animal models dealing with muscle atrophy, aging, or injury recovery, IGF-1 LR3 administration is often linked to better lean mass preservation and improved fibre cross-sectional area. It also seems to help strength bounce back faster after periods of disuse or immobilisation. These results have put IGF-1 LR3 right at the crossroads of muscle biology and geroscience, especially since keeping muscle mass intact in aging populations has become such a major research priority.

Comparing IGF-1 LR3 with upstream GH/IGF-1 axis stimulators — like Sermorelin 2mg, Tesamorelin 2mg, and Ipamorelin 2mg — helps us characterise how pituitary-driven IGF-1 elevation differs from direct receptor stimulation. It is a key way to look at downstream anabolic effects. These comparisons aren’t just useful; they’re vital for any mechanistic study of the somatotropic axis.

Laboratory Handling

We supply IGF-1 LR3 1mg as a lyophilised white powder. To keep the peptide soluble, you’ll typically need to reconstitute it in 0.1% acetic acid before diluting it further in sterile PBS or a culture medium. It’s best to aliquot the solution and store it at −20°C, though you can keep working aliquots at 4°C for short-term use. Just make sure to avoid repeated freeze-thaw cycles. This research-grade material is characterised by an HPLC purity verification of ≥95%. This product is for research purposes only and is not intended for human administration; it should only be handled by qualified investigators.

For research purposes only. Not intended for human administration.

References

• Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3–34.
• Ren H, et al. IGF-1 LR3 enhances proliferation and differentiation of myogenic cells. J Muscle Res Cell Motil. 2010;31(4):257–265.
• Musarò A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27(2):195–200.
• Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012;41(2):425–443.

For more information on IGF-1 LR3 please visit Wikipedia.